Reports
The following list of reports reflects the latest in findings and outcomes in medical research as presented at major medical meetings and published peer-reviewed medical journals. In this section you can view reports from important congresses as well as summaries of some recently published journal articles. Please let us know if you have a particular area of interest you would like to see covered.
MEDICAL FRONTIERS - A report from recent peer-reviewed publications and medical conferences
New Overview of Biologic Therapy Risks in Psoriasis
May 2011
The ability of highly targeted biologic agents to halt psoriasis and other inflammatory processes, first achieved with tumour necrosis factor alpha (TNF-a) inhibitors, has been a revolutionary advance for intractable cases. In psoriasis,...
MEDI-NEWS - Based on: Lanzl I, Raber T. Efficacy and tolerability of the fixed combination of brinzolamide 1% and timolol 0.5% in daily practice. Clin Ophthalmol 2011;5:291-8.
Novel Combination Therapy for Intraocular Pressure: Achieving Greater Efficacy and Patient Satisfaction
May 2011
Finding the Optimal Combination for Efficacy and Tolerability Most individuals with elevated intraocular pressure (IOP) fail to achieve adequate control on a single agent. Over the past decade, the effort to incorporate 2...
PRIORITY PRESS - 12th Annual European Congress of Rheumatology (EULAR)
Success of Biologics in Rheumatoid Arthritis: From Efficacy of IL-6 Inhibition to Validation of Targeting New Inflammatory Pathways
London, UK / May 25-28, 2011
London - Current biologics, which include tumour necrosis factor (TNF) and interleukin-6 (IL-6) receptor inhibitors, act by exerting control over key molecular steps in the inflammatory process of rheumatoid arthritis (RA). Their ability to...
PRIORITY PRESS - 12th Annual European Congress of Rheumatology (EULAR)
Insights Into Tight Rheumatoid Arthritis Control and Treating-to-Target Approaches
London, UK / May 25-28, 2011
London - Experts at this year’s EULAR agreed that rapid control of inflammation is essential in rheumatoid arthritis (RA). In 2010, the EULAR guidelines were revised to define the treatment goal as an absence of signs and symptoms as well...
PRIORITY PRESS - 12th Annual European Congress of Rheumatology (EULAR)
New Treatment Option for Gout-related Hyperuricemia
London, UK / May 25-28, 2011
Until recently, treatment of gout involved either enhancement of renal uric acid excretion with a uricosuric, such as probenecid, or inhibition of urate production with the purine-based analogue allopurinol, a xanthine oxidase inhibitor....
PRIORITY PRESS - 22nd World Congress of Dermatology
Reducing Flares in Atopic Dermatitis by Managing Subclinical Inflammation
Seoul, South Korea / May 24-29, 2011
Chief Medical Editor: Dr. Léna Coïc, Montréal, Quebec Pathophysiology As explained here at the WCD by Dr. Michael Cork, Head, Academic Unit of Dermatology Research, The University of Sheffield, UK, an intact stratum...
JOURNAL CLUB - HIV/AIDS
New Guidelines to Identify Appropriate Use of CCR5 Inhibitors in HIV/AIDS
May 2011
Editorial Review Sharon L. Walmsley, MD, FRCPC, MSc, Director, HIV Clinical Research, University Health Network, Professor of Medicine, Division of Infectious Diseases, University of Toronto, Toronto,...
PRIORITY PRESS - 2011 American Thoracic Society International Conference
Asthma Control with Inhaled Corticosteroids in the Typical Clinical Setting
Denver, Colorado / May 13-18, 2011
Denver - Prospective, carefully controlled randomized clinical trials often exclude the very patients that are seen by most general practitioners. Retrospective rigorously conducted observational studies look closely at patients who have...
MEDICAL FRONTIERS - A report from recent peer-reviewed publications
Safety Concerns of Statins Allayed After Long Experience with the Most Potent Agents
May 2011
Statins are among the most widely prescribed therapies of any kind. Their high degree of efficacy for reducing the risk of cardiovascular (CV) events has been documented in a series of multinational and landmark trials that underlie the...